Comparison of Efficacy between Switching Intravitreal Ranibizumab and Aflibercept Injection in Non-responsive Neovascular Age-related Macular Degeneration Treated with Bevacizumab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190928003

Enrollment

Registered

2019-09-28

Start date

2019-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non&#45

Interventions

responsive Neovascular Age&#45

related Macular Degeneration Treated with Bevacizumab participant will randomized into 2 groups as ranibizumab group and aflibercept group by compute&#45

generated block randomization &#45

Baseline data i.g. best corrected visual acuity&#44

central macular thickness collect from participants before switch to ranibizumab &#45

Paticipant treat by intravitral injection monthly &#45

Outcome data i.g. best corrected visual acuity&#44

central macular thickness&#44

color fundus photography collect after 3 months switching intravitral injection ,Non&#45

central macular thickness collect from participants before switch to aflibercept &#45

color fundus photography collect after 3 months switching intravitral injection

Active Comparator Drug,Active Comparator Drug

Non&#45

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria Participant who was diagnosed as neovascular age-related macular degeneration and treated with intravitral Bevacizumab monthly at least 3 times and not responded to treatment which have one of these following conditions 1. Best corrected visual acuity not better than 5 letters or worst than baseline visual acuity 2.Macular edema or central macular thinkness decress less than 10 percent from baseline central macular thickness 3.New macular hemorrhage

Exclusion criteria

Exclusion criteria: Exclusion criteria 1.Patient who was treated with intravitral Ranibizumab or Aflibercept 2.Patient who was treated laser at macular 3.Patient who have other retinal diseases which cause macular edema e.g. Macular edema after surgery, diabetic macular edema 4.Eye diseases which interrupted research evaluation or affect to vision or have to treated with other medicines/ undergo surgery e.g. Worsen cataract, glaucoma, central retinal vein/artery occlusion

Design outcomes

Primary

Measure	Time frame
Best corrected visual acuit 3 months Early Treatment Diabetic Retinopathy Study (ETDRS) Chart	—

Secondary

Measure	Time frame
central macular thickness 3 months Optical Coherence Tomography : OCT	—

Countries

Thailand

Contacts

Public ContactFlt.Lt.Arissara Warichtrakul

Department of ophthalmology,Phramongkutklao hospital

evearisara@hotmail.com085-061-5432

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Comparison of Efficacy between Switching Intravitreal Ranibizumab and Aflibercept Injection in Non&#45;responsive Neovascular Age&#45;related Macular Degeneration Treated with Bevacizumab